Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management

Jayesh Desai, Howard Gurney, Nick Pavlakis, Grant A. Mcarthur, Ian D. Davis

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Sunitinib malate (SU011248, Sutent®[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand-foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.

LanguageEnglish
Pages167-176
Number of pages10
JournalAsia-Pacific Journal of Clinical Oncology
Volume3
Issue number4
DOIs
Publication statusPublished - Dec 2007
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Renal Cell Carcinoma
Hand-Foot Syndrome
Therapeutics
Lethargy
Stomatitis
Hypothyroidism
Neutropenia
Thrombocytopenia
Protein-Tyrosine Kinases
Diarrhea
sunitinib
Clinical Trials
Hypertension
Pharmaceutical Preparations

Keywords

  • Gastrointestinal stromal tumor (GIST)
  • Multitargeted tyrosine kinase inhibitor (TKI)
  • Renal cell carcinoma (RCC)
  • Sunitinib

Cite this

@article{45708ff48e4f4510bb284e05795bba60,
title = "Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management",
abstract = "Sunitinib malate (SU011248, Sutent{\circledR}[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand-foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.",
keywords = "Gastrointestinal stromal tumor (GIST), Multitargeted tyrosine kinase inhibitor (TKI), Renal cell carcinoma (RCC), Sunitinib",
author = "Jayesh Desai and Howard Gurney and Nick Pavlakis and Mcarthur, {Grant A.} and Davis, {Ian D.}",
year = "2007",
month = "12",
doi = "10.1111/j.1743-7563.2007.00136.x",
language = "English",
volume = "3",
pages = "167--176",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell, Wiley",
number = "4",

}

Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor : Recommendations for patient management. / Desai, Jayesh; Gurney, Howard; Pavlakis, Nick; Mcarthur, Grant A.; Davis, Ian D.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 3, No. 4, 12.2007, p. 167-176.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor

T2 - Asia-Pacific Journal of Clinical Oncology

AU - Desai, Jayesh

AU - Gurney, Howard

AU - Pavlakis, Nick

AU - Mcarthur, Grant A.

AU - Davis, Ian D.

PY - 2007/12

Y1 - 2007/12

N2 - Sunitinib malate (SU011248, Sutent®[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand-foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.

AB - Sunitinib malate (SU011248, Sutent®[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand-foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.

KW - Gastrointestinal stromal tumor (GIST)

KW - Multitargeted tyrosine kinase inhibitor (TKI)

KW - Renal cell carcinoma (RCC)

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=36749047492&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2007.00136.x

DO - 10.1111/j.1743-7563.2007.00136.x

M3 - Review article

VL - 3

SP - 167

EP - 176

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 4

ER -